BioArctic AB (publ) (STO:BIOA.B)
Sweden flag Sweden · Delayed Price · Currency is SEK
208.00
-7.40 (-3.44%)
Aug 1, 2025, 10:47 AM CET

BioArctic AB Company Description

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden.

It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs.

The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.

In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies.

Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage.

It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016.

BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

BioArctic AB (publ)
BioArctic AB logo
CountrySweden
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees107
CEOGunilla Osswald

Contact Details

Address:
Warfvinges vag 35
Stockholm, 112 51
Sweden
Phone46 86 95 69 30
Websitebioarctic.se

Stock Details

Ticker SymbolBIOA.B
ExchangeNasdaq Stockholm
Share ClassClass B Shares
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0010323311
SIC Code2836

Key Executives

NamePosition
Dr. Gunilla Osswald Ph.D.President and Chief Executive Officer
Dr. Pär GellerforsCo-Founder, Senior Vice President of Business Strategy and Director
Prof. Lars LannfeltCo-Founder, Senior Vice President of Medical science and Director
Anders Martin-Lof M.B.A., M.Sc.Chief Financial Officer
Johanna FältingChief Research & Development Officer and Head of Research and Development
Christer MöllerVice President of Pre-Clinical Development and Chief Scientific Officer
Oskar BossonVice President and Head of IR and Communication
Leif Gallo LL.M.General Counsel and Head of Legal and IP
Harald BorgekeHead of Public Affairs
Frida LekanderHead of Marketing